Lumida
/INBX
⌘K
Inhibrx Biosciences Inc

Inhibrx Biosciences Inc

INBX
$109.27USD-1.93%-2.15 today

MARKET CAP

1.6B

P/E (TTM)

FWD P/E

DAY RANGE

$109 – $115

52W RANGE

$26
$155

AI Summary

Stalk
StalkMedium

INBX displayed a Bearish Exhaustion candle at a key support area, signaling a potential bottoming bounce into the 50-day SMA and 200-day SMA zone. While medium-term bias remains bullish under the higher-highs higher-lows regime and exhaustion signal, price currently sits below the 9- and 20-period EMAs and requires a clearer acceptance of the support zone. Execution will be deferred until pullbacks into this structural support are reliably held.

  • FDA accepted ozekibart BLA for oncology; review set April 14, 2027.
  • $325 M debt facility (Oxford Finance) with $100 M funded in July for R&D.
  • Q2 2026 net loss $36.7 M ($2.34/share) underscores weak profitability.
Full analysis →
Insider Trades5 trades
DateSideTickerInsiderRoleSharesPriceMkt Cap52W High52W LowValue% ChgRuleAI View
Sep 12, 2024BuyINBXMark LappeChief Executive Officer40,000$15.73$1.6B-29.63%+317.22%$629.1K+2.95%Sell Now
Sep 6, 2024BuyINBXMark LappeChief Executive Officer44,000$15.25$1.6B-29.63%+317.22%$671.1K+2.28%Sell Now
Aug 29, 2024BuyINBXMark LappeChief Executive Officer40,000$14.92$1.6B-29.63%+317.22%$596.8K+7.08%Sell Now
Aug 20, 2024BuyINBXMark LappeChief Executive Officer40,000$12.96$1.6B-29.63%+317.22%$518.3K+70.44%Sell Now
May 28, 2024SellINBXBrendan P. EckelmanChief Scientific Officer300,000$34.30$1.6B-29.63%+317.22%$10.3M-14.74%Sell Now